실시간
FierceBiotechFueled by M&A and partnerships, biotech is poised for continued growth: EYFierceBiotechGalmed acquires Colospan in $4.5M deal as it eyes $6B GI dx marketBioPharma DiveMerck, Gilead report mixed outcomes in key lung cancer, HIV studiesEndpoints NewsA different approach to lowering healthcare costsCellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activityClinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics DiagnosticsBioPharma DiveStealthy startup Treeline plans a reverse merger10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybizEndpoints NewsHow K Health moved AI chatbots into hospitals10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpaceEndpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV success
eLife 2026년 3월 10일

<i>EPB41L4A-AS1</i> long noncoding RNA acts in both <i>cis</i>- and <i>trans</i>-acting transcriptional regulation and controls nucleolar biology

EPB41L4A-AS1 long noncoding RNA acts in both cis - and trans -acting transcriptional regulation and controls nucleolar biology

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.